Related Experiment Video
Updated: Aug 4, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab has bidirectional regulatory effects on the secretion of basic fibroblast growth factor in glioma cells
Pei Wei1, Zhainan Zhang2, Mao Lin2
1Department of Immunology, Zhuhai Campus of Zunyi Medical University, Zhuhai, China; Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Dongguan, China.
Abstract:
Previous studies suggest that upregulated basic fibroblast growth factor (bFGF) plays a key role in the resistance to anti-vascular endothelial growth factor (VEGF) therapy in glioma. This study reported that anti-VEGF treatment regulated bFGF secretion in a double-edged manner. That is, moderate VEGF neutralization reduced bFGF production, whereas VEGF overblocking enhanced bFGF secretion in glioma cells. Our data provide a new perspective on the treatment of glioma with anti-VEGF, and the underlying mechanism is worthy of further study.
Insights
Anti-vascular endothelial growth factor (VEGF) therapy resistance in glioma is linked to basic fibroblast growth factor (bFGF). This study found that VEGF neutralization impacts bFGF secretion differently, offering new insights into glioma treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Basic fibroblast growth factor (bFGF) is implicated in resistance to anti-vascular endothelial growth factor (VEGF) therapy in glioma.
- Understanding the interplay between VEGF and bFGF is crucial for optimizing glioma treatment.
Purpose of the Study:
- To investigate the effect of anti-VEGF treatment on bFGF secretion in glioma cells.
- To elucidate the dual role of VEGF neutralization in regulating bFGF production.
Main Methods:
- Glioma cell culture models were utilized.
- Vascular endothelial growth factor (VEGF) neutralization was performed at varying concentrations.
- Basic fibroblast growth factor (bFGF) secretion levels were quantified.
Main Results:
- Moderate VEGF neutralization led to reduced bFGF production in glioma cells.
- Excessive VEGF overblocking resulted in enhanced bFGF secretion from glioma cells.
- A dose-dependent, double-edged effect of anti-VEGF on bFGF secretion was observed.
Conclusions:
- The efficacy of anti-VEGF therapy in glioma may depend on the degree of VEGF neutralization.
- The observed regulation of bFGF by anti-VEGF presents a novel perspective for glioma treatment.
- Further investigation into the underlying mechanisms is warranted to refine therapeutic strategies.
